Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
To Investigate the Blood Concentration of Liraglutide as Well as the Effects on Glucose and Insulin After 21 Days of Daily Subcutaneous Injections of Liraglutide or Placebo
- First Posted Date
- 2008-09-29
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 37
- Registration Number
- NCT00761540
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Beijing, Beijing, China
Comparison of Insulin Detemir and NPH With Respect to Lowering the Blood Sugar and Symptoms Experienced by Type 1 Diabetics During Hypoglycaemia
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- First Posted Date
- 2008-09-26
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 25
- Registration Number
- NCT00760448
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Guildford, United Kingdom
Observational Study of NovoMix® 50 for Treatment of Type 2 Diabetics for 12 Months
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- Drug: biphasic insulin aspart 50
- First Posted Date
- 2008-09-19
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 270
- Registration Number
- NCT00755833
- Locations
- 🇸🇮
Novo Nordisk Investigational Site, Ljubljana, Slovenia
Switch From Metformin Monotherapy to a Bitherapy With Metformin and Repaglinide
- First Posted Date
- 2008-09-03
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 906
- Registration Number
- NCT00745433
Observational Study on Safety of Self-titration of Once Daily Levemir®
- First Posted Date
- 2008-08-25
- Last Posted Date
- 2017-02-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 882
- Registration Number
- NCT00740519
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Crawley, United Kingdom
Observational Study on Efficacy and Safety in Patients Using NovoMix® 30 for the Treatment of Diabetes
Completed
- Conditions
- Diabetes Mellitus, Type 1DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-08-20
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1068
- Registration Number
- NCT00737776
- Locations
- 🇰🇷
Novo Nordisk Investigational Site, Seoul, Korea, Republic of
An Observational Study on Efficacy and Safety in Subjects Using Levemir® for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes
Completed
- Conditions
- Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2008-08-20
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 798
- Registration Number
- NCT00738153
Observational Study to Observe the Safety of Levemir® Treatment in Patients With Type 2 Diabetes
- First Posted Date
- 2008-08-15
- Last Posted Date
- 2014-10-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 314
- Registration Number
- NCT00735501
Observational Study to Observe the Safety of NovoMix® 30 Treatment in Patients With Type 2 Diabetes
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 243
- Registration Number
- NCT00729898
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Farsta, Sweden
Examination of the Safety and Tolerability of NNC 0070-0002-0349 in Overweight/Obese Volunteers
Phase 1
Withdrawn
- Conditions
- ObesityMetabolism and Nutrition Disorder
- Interventions
- Drug: NNC 0070-0002-0349Drug: placebo
- First Posted Date
- 2008-08-05
- Last Posted Date
- 2014-10-17
- Lead Sponsor
- Novo Nordisk A/S
- Registration Number
- NCT00728455
© Copyright 2025. All Rights Reserved by MedPath